At EURETINA 2026, Jordi Monés, MD, PhD, outlined the rationale for gene-agnostic optogenetic therapy MCO-010 to restore vision in Stargardt disease and geographic atrophy.
Jordi Mones, MD, PhD
Advertisement
Jordi Monés, MD, PhD, is director of Institut de la Màcula in Barcelona, Spain, and adjunct professor at the John A. Moran Eye Center, University of Utah in Salt Lake City.
Articles by Jordi Mones, MD, PhD
Jordi Mones, MD, PhD, discusses what is believed to be the first direct-to-phase 2 trial testing an optogenetic gene therapy to restore vision lost to GA.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: Tinlarebant in Stargardt disease: Jacque Duncan, MD, on DRAGON results
2
AAO 2026: MCO-010 sustains vision gains in RP through 4 years
3
AAO 2026: What the first whole eye transplant has taught surgeons
4
AAO 2026: What the evidence really shows about nutrition and the eye
5